The ethical dilemma of gene editing: Our reporter took your questions
By Carolyn Y. Johnson,
The Washington Post [cites CGS’ Pete Shanks ]
| 12. 08. 2023
The first medicine based on gene editing, a one-time therapy for sickle cell disease, was just approved in the United States. It’s a big moment for patients with sickle cell disease and for the technology called CRISPR, which powers the therapy.
I am Carolyn Johnson, a science reporter at The Washington Post, and I’ve been following the speedy trajectory of CRISPR from a scientific breakthrough in 2012 to a medicine that can alleviate human suffering 11 years later. On Tuesday, I answered your questions about the potential of this technology to transform medicine — and the challenges associated with it.
First, a quick primer: CRISPR is often compared to a pair of “molecular scissors” that can make targeted cuts in DNA, giving scientists the ability to easily and precisely alter the genome. Scientists often hear from families afflicted by genetic diseases hoping that this technology will help save their loved ones. It has also spurred controversies — including battles over who invented CRISPR and the fear that it will be used to create “designer babies.”
Here...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...